Anti-cancer immunotherapeutic composition for treating cancer
AssigneeInteroligo Corporation
InventorsJung Hwan LEE, Jong Ook LEE, Jin Woo KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to an aptamer or a functional fragment thereof, capable of specifically binding to PD-L1 or capable of inhibiting interaction between PD-1 and PD-L1 by specifically binding to PD-L1, which includes a nucleic acid sequence of SEQ ID NO. 1, 2, 10 or 18.
Claims14
An aptamer or a functional fragment thereof, capable of specifically binding to programmed death-ligand 1 (PD-L1) or capable of inhibiting interaction between programmed cell death protein 1 (PD-1) and PD-L1 by specifically binding to PD-L1, the aptamer comprising a nucleic acid sequence of SEQ ID NO:
- 1, 2, 10 or 18.
A method for treating cancer, comprising administering to a subject in need thereof a composition comprising at least one of an aptamer and a functional fragment thereof, the aptamer comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1, 2, 10, and 18.
A method for detecting cancer cells, comprising administering to a subject in need thereof a composition comprising at least one of an aptamer and a functional fragment thereof, the aptamer comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 1, 2, 10 and 18.
Dependencies are inferred from the claim text.